Guardant Health (GH) reported Thursday Q2 adjusted loss of $0.42 per diluted share, compared with a loss of $0.44 a year earlier.
Analysts polled by FactSet expected loss of $0.39.
Revenue for the quarter ended June 30 was $335.0 million, up from $232.1 million a year ago.
Analysts expected $314.2 million.
The company now expects full year 2026 revenue between $1.34 billion and $1.36 billion, up from $1.30 billion to $1.32 billion earlier. Analysts expect $1.31 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.